Innovative Antibody Discovery With Super-trillion Ab Libraries

Considering current problems of antibody preparation technology, such as extended preparation cycle, heavy screening workload, and limited number of candidate antibodies, especially difficulty for challenging targets, We have built a "Super-trillion Innovative Antibody Discovery Platform" characterized by technology integration with comprehensive fundamental solution to the screening of innovative antibody candidate molecules.

In this platform, animal immunity, fully human or immune source-derived recombinant B-cell antibodies, construction of synthetic and semi-synthetic antibody library, phage display antibody library, mammalian cell expression of recombinant antibody, automation and high-throughput screening were integrated. 

Service Highlights

The trillion library matrix integrates antibody generation technologies such as "fully human natural B cells, alpaca/mouse immune B cells, single domain antibodies, recombinant antibodies, synthetic antibodies, and semi- synthetic antibodies", which meet the needs of all types of molecules, including "fully human antibodies, humanized single domain antibodies, humanized mouse monoclonal antibodies, bispecific monoclonal antibodies, polyclonal antibodies, polypeptides, ADC, PDC, and miniaturized proteins", and is capable of obtaining candidate molecules at high speed and high success rate which are close to nature with high affinity, high druggability and high developability.

1.Trillion fully human recombinant antibody library

• Trillion library capacity.

• Recombinant antibody library of fully human B cells after cloning.

• Coming from nature with good developability.

• Lead molecule median: 300+.

2. Trillion fully human semi-synthetic antibody library

• Trillion library capacity.

• Antibody library of fully human B cells after rearrangement.

• Coming from nature with engineering design and great diversity.

• Lead molecule median: 300+.

3. Trillion fully human 2C-type single domain antibody library

• 2-trillion library capacity.

• Humanization degree of antibody framework reaches 98%.

• 2C-type single domain synthetic antibody library.

• Lead molecule median: 600+.

4. Trillion fully human 4C-type single domain antibody library

• 2-trillion library capacity.

• Humanization degree of antibody framework reaches 98%.

• 4C-type single domain synthetic antibody library that is more stable and more degradation-resistant.

• Lead molecule median: 600+.

5. Trillion fully human common light chain monoclonal antibody library

• Trillion library capacity.

• Recombinant antibody library with a combination of selected light chains and diversified heavy chains.

• Coming from fully human natural antibodies, with selected light chains and diversified heavy chains.

• Lead molecule median: 300+.

6. Trillion cyclic polypeptide library

• Trillion library capacity.

• A cyclic polypeptide library with fusion of selected tagged proteins and natural cyclic polypeptides.

• Suitable for the drug R&D of PDC, oral, and intracellular target.

• Lead molecule median (estimated): 100+.

7. Magnetic & Immunization & Tandem mouse antibody library

• Large library capacity and clear sequences saving several months compared with hybridoma.

• Diversified antigens, mouse, immune pathway, and cross screening.

• Recombinant antibody library of mouse B cells cloning after immunization.

• Lead molecule median: 40+.

8. Magnetic & Immunization & Tandem alpaca antibody library

• Large library capacity and clear sequences.

• Diversified antigens, immune pathway, and cross screening.

• Single domain antibody obtained directly.

• Lead molecule median: 30+.